skip to content

CHMP recommends EU approval of Roche’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.